Indian Journal of Cancer Home 

MINI SYMPOSIUM: HEAD AND NECK
[View FULLTEXT] [Download PDF]
Year : 2012  |  Volume : 49  |  Issue : 1  |  Page : 1--5

Palliative weekly chemotherapy along with cetuximab in recurrent and metastatic head and neck cancers: A retrospective analysis

RR Rangaraju1, JB Sharma1, AK Dewan2, AK Anand3, Rawat Sheh4, A Jena5, AK Chaturvedi6 
1 Senior Consultant Medical Oncology, BLKCC, Senior Consultant Medical Oncology, Action Balaji Cancer Hospital, New Delhi, India
2 Director HN Surgical Oncology, Rajiv Gandhi Cancer Institute, New Delhi, India
3 Director Radiation Oncology, Max Cancer centre, Saket, New Delhi, India
4 Senior Consultant, Radiation Oncology, RGCI, New Delhi, India
5 Senior consultant MRI, RGCI, New Delhi, India
6 Senior Consultant Imaging, RGCI, New Delhi, India

Correspondence Address:
R R Rangaraju
Senior Consultant Medical Oncology, BLKCC, Senior Consultant Medical Oncology, Action Balaji Cancer Hospital, New Delhi
India

Background: This study was undertaken to report the results of weekly combination chemotherapy with cetuximab in recurrent/metastatic head and neck squamous cell carcinoma (R/M SCCHN). Materials and Methods: Retrospective analysis of 35 R/M SCCHN patients who received cetuximab with weekly paclitaxel and platin (cisplatin/carboplatin) from SCCHN August 2006 to October 2008 at our Institute was performed. Results: Thirty-five patients (33 [94.3%] males and 2 [5.7%] females) received the planned weekly chemotherapy protocol. Median age of these patients was 52 years. Of the SCCHN 32 evaluable patients, 25 patients showed symptomatic improvement and 7 showed no improvement. Radiological responses using RECIST criteria reported CR in 1 patient (3.1%), PR in 17 patients (53.1%), and SD in 6 patients (18.8%). The remaining six patients demonstrated disease progression while two could not be assessed. Median overall survival (OS) was 8.016 months (95% CI; 6.572--9.461) and median PFS was 5.782 months (95% CI; 4.521--7.044). The major chemotherapy-related grades 2 and 3 toxicity recorded was cetuximab-induced rash reported in 24 patients. No treatment-related death within 30 days was observed. Conclusion: Cetuximab with weekly combination chemotherapy (Paclitaxel + Platinum compound) has shown promise, demonstrating comparable response and outcomes with acceptable toxicity in R/M SCCHN patients.


How to cite this article:
Rangaraju R R, Sharma J B, Dewan A K, Anand A K, Sheh R, Jena A, Chaturvedi A K. Palliative weekly chemotherapy along with cetuximab in recurrent and metastatic head and neck cancers: A retrospective analysis.Indian J Cancer 2012;49:1-5


How to cite this URL:
Rangaraju R R, Sharma J B, Dewan A K, Anand A K, Sheh R, Jena A, Chaturvedi A K. Palliative weekly chemotherapy along with cetuximab in recurrent and metastatic head and neck cancers: A retrospective analysis. Indian J Cancer [serial online] 2012 [cited 2022 Jan 27 ];49:1-5
Available from: https://www.indianjcancer.com/article.asp?issn=0019-509X;year=2012;volume=49;issue=1;spage=1;epage=5;aulast=Rangaraju;type=0